AzTrials
AzTrials

ImmunodeficiencySAIDNCT06248957

SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION

An observational study of Immunodeficiency and Autoimmune Diseases, run by Karolinska Institutet at 1 site in Sweden.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
What is being tested?
Immunomodulation
How many people
500 participants
Where
1 siteSweden
Study dates
1 Jan 2024to 31 Dec 2031
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: All subjects, children and adults in Sweden and referred to Swedish centers with known or suspected immune dysregulation.

Who may be able to join

  • Patients of all ages seeking care or being referred for suspected immune dysregulation or with a known immune-mediated disease and failing to respond to standard therapy

Who cannot join

  • Healthy control individuals will be excluded on the basis of having a diagnosis of an immune mediated disorder, immunomodulatory treatment or current infection or cancer.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Petter Brodin, M.D., Ph.D contact

08 524 813 96 ext. +46

petter.brodin@ki.se

Genia Kretzschmar, M.D contact

genia.kretzschmar@ki.se

Sweden1 site, 1 recruiting
  • Karolinska Institutet

    Stockholm, SE171 77

    Petter Brodin, MD PhD, +46 8 52481396, petter.brodin@ki.se

    Petter Brodin, MD PhD

    Recruiting

Other trials in Sweden

About this study

The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. We hope to establish a biobank of primarily blood and fecal samples from children and adults, with confirmed or suspected immune dysregulation, as well as age- and sex- matched healthy controls, for comparisons of immune cell/mediator alongside various clinical presentations of these immunological diseases as well as microbiome samples as possible a possible modifier of clinical presentations. The project will also include the establishment of a national database with deep immunological data, treatment and clinical outcomes for these patients, accessible to participating researchers and clinicians.

Read the detailed description

BACKGROUND

Immune dysregulation encompasses multiple different conditions in which the immune system does not function properly and displays inappropriate or inadequate responses, overreactions or under-reactions directed towards external or internal targets. It is a broad term, and its manifestations include several different categories of disease:

Immunodeficiencies: These disorders impair the immune system's ability to defend the body against foreign or abnormal cells that invade or attack it (such as bacteria, viruses, fungi, and cancer cells). As a result, unusual bacterial, viral, or fungal infections or lymphomas or other cancers may develop. Primary immunodeficiencies (PIDs) comprise a group of nearly 500 inherited disorders, often due to single-gene mutations that result in the specific impairments in immune function. Secondary immunodeficiencies (SIDs) involve a weakened immune system caused by external sources e.g. chemical (chemotherapy), infection (HIV) or cancer.

Autoimmune Disorders: In these conditions the production of autoantibodies against self-antigens causes the immune system to attack healthy cells and tissues. Some of the most common examples include type 1 diabetes (T1D), rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE).

Autoinflammatory Disorders: Here dysregulation of the innate immune system leads to spontaneous and recurrent inflammatory episodes. In contrast to autoimmune diseases where antibodies against self-antigens play a central role, the defect in autoinflammatory diseases often lies in the first responder, innate, arm of the immune system where the defect triggers inappropriate activation of the normal inflammatory response or disables resolution thereof. Examples include familial Mediterranean fever (FMF) and cryopyrin-associated periodic syndromes.

Severe allergies: Allergic reactions are misdirected reactions of the immune system to substances commonly found in the environment. Allergens elicit a T helper 2 immune response, including the involvement of IgE, mast cells, innate lymphoid cells 2 (ILC2), eosinophils, and basophils. Severe Allergy which does not respond to therapy can also indicate underlying immundysregulation.

Lymphoproliferation: Lymphoproliferation (LP) refers to persistent polyclonal, oligoclonal, or monoclonal proliferation of lymphoid cells in the clinical setting of immune dysregulation. Symptoms are non-specific and mimic those of an infection, inflammation, or neoplasia and are characterized by chronic or recurrent lymphadenopathy, hepatosplenomegaly, extranodal infiltration, and/or peripheral blood lymphocytosis. Immune disorders characterized by LP include autoimmune lymphoproliferative syndrome (ALPS) and X-linked lymphoproliferation (XLP).

Attempting to classify and group disorders of immune dysregulation in this way is of course an over-simplification as exemplified by conditions with both autoimmune and autoinflammatory components, such as psoriasis or IBD. For this reason, it has been proposed that manifestations of immune dysregulation should be considered as a continuum with rare monogenic autoimmune disorders at one end, rare monogenic autoinflammatory disorders at the other end, followed by polygenic autoimmune/autoinflammatory conditions respectively, with mixed pattern diseases in the center. In real life, patients with immune dysregulation also often present with more than one disease manifestation which further complicates diagnosis and treatment.

Finally, another factor that must be considered when trying to understand immune dysregulation, is the influence of the microbiome. Disruptions to the microbiota early in life are known to have lasting health effects, including increased risks of immune- mediated diseases such as allergy. However, less is known about the possibility that inborn errors of immunity may also shape the developing microbiome with ensuing health-related consequences, although the role of the microbiome in immune dysfunction is beginning to be appreciated. For example, impaired immunity may alter the intestinal microbiome causing subsequent increased intestinal permeability, with increased exposure to bacterial DNA and an activation of innate and adaptive immune that ultimately perpetuate or exacerbate any defects in immunity.

THE PROBLEM Certain types of immune dysregulation can be extremely rare and diagnosis and appropriate treatment are complicated issues. Some are caused by specific genetic mutations with on average one new genetic mutation associated with immune dysregulation being discovered every month. However, in over half of patients with e.g. autoinflammatory disorders, no genetic cause can be found. Some disorders also affect multiple branches of the immune system due to a broader inappropriate immune response, where signs and symptoms of autoimmunity, allergy, and/or immunodeficiency can all be present in one condition at the same time. A new approach is therefore essential to facilitate diagnosis and personalized treatment of patients with immune dysregulation which we believe will involve more holistic, systems-level analyses of immune cell composition and functional responses. Furthermore, little is known about the interaction between the immune function and microbiome composition, particularly in relation to immune dysregulation, and understanding this interplay may reveal new therapeutic opportunities and enable prediction of adverse outcomes.

SYSTEMS IMMUNOLOGY The human immune system consists of many specialized cell populations that stimulate each other to respond, but also compete for growth factors and directly suppress each other to prevent immune pathology. In this way the whole system functions as a highly integrated network. Since this network is decentralized without any master regulator, all actions in the system, both productive immune responses to microbes and destructive autoimmune attacks on normal tissues, emerge from the combined actions of the many immune cell populations that make up this network. To understand higher order functions in a system this complex, comprehensive analyses involving all cell populations simultaneously are required. Only then can the consequence of activating one, or a few specific cell populations, in the system as a whole be understood. This realization has led to the pursuit of "Systems Immunology", the application of technologies and theories from the field of Systems Biology to understand immune systems. Technological advances, primarily in mass cytometry for high- dimensional immune cell analysis, and high-throughput serum protein analyses, now allow for such detailed profiling of all components that make up human immune systems. We therefore now have the ability to dissect immune responses into their underlying cell-cell and cell-protein interactions.

SCIENTIFIC HYPOTHESIS

  • Systems-level analyses of immune cell composition and functional responses can reveal distinct cellular networks and pathways related to immune dysregulation in patients with systemic inflammation and immune dysregulation of unknown cause, providing new targets for treatment and facilitating diagnosis.
  • Inter-individual variation in systemic inflammatory diseases could be explained by differences in microbial colonization. We hypothesize that microbiome compositional differences can explain differences among patients with defects in similar immune system pathways.
  • By combining systems-level functional analyses with whole genome sequencing (clinical analyses) we can better understand redundant pathways in human immune systems which modulate phenotypes in patients with systemic inflammatory and immune dysregulation diseases.
Being tested
Immunomodulation
Medical subject headings
Immunologic Deficiency Syndromes, Autoimmune Diseases, Hypersensitivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ImmunomodulationCombination product

    Variable protocols for combined immunomodulatory therapies currently in use for different forms of immune dysregulation

Study groups in NCT06248957
Study groupRoleWhat they receive
Patients with immune dysregulationPatients sampled before and during different immunomodulatory therapies due to immune system dysregulation.
Receives: Combination Product: Immunomodulation
Healthy subjectsAge-matched healthy individuals sampled longitudinally

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. control of immune dysregulation

    Remission and control of immune dysregulation manifested as reduced inflammation, symptom relieve and halted immunoproliferation for examples

    Measured: 1-3 months from start of therapy

Secondary outcomes (1)
  1. Exploratory immunological parameters

    Systems-level immunomonitoring for exploration of cell state changes in response to therapy

    Measured: 1-3 months from start of therapy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2024
  2. Study start1 Jan 2024
  3. Primary completion31 Dec 2030 (estimated)
  4. Study completion31 Dec 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
500 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06248957
Sponsor's protocol ID
2023-06579-01
Other IDs
2023
Acronym
SAID
Status last verified
Jan 2024
First submitted
31 Jan 2024
Last updated
8 Feb 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Immunodeficiency and Autoimmune Diseases, run by Karolinska Institutet at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 8 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Petter Brodin, M.D., Ph.D (08 524 813 96 ext. +46, petter.brodin@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

control of immune dysregulation (time frame: 1-3 months from start of therapy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in